NEFL and myeloid sarcoma: The 2021 Consortium of Multiple Sclerosis Centers (CMSC) Consensus Statement on Neurofilament Biomarkers in MS highlighted potential applications for NfL measurements for clinical decision-making during the course of MS, adding that serum and/or CSF NfL could complement MRI monitoring for detecting underlying inflammatory activity and informing risk of future MS disease burden [84].